UBS Maintains Neutral on AbbVie, Raises Price Target to $200
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Navin Jacob maintains a Neutral rating on AbbVie (NYSE:ABBV) and raises the price target from $195 to $200.
October 31, 2024 | 7:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS analyst Navin Jacob has maintained a Neutral rating on AbbVie and increased the price target from $195 to $200, indicating a slight positive outlook.
The increase in the price target from $195 to $200 suggests a slightly more positive outlook on AbbVie's stock, which could lead to a minor upward movement in the stock price. However, the Neutral rating indicates that the analyst does not expect significant outperformance.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100